英诺特：2025年营收4.22亿元，净利润同比降40.84%

Core Viewpoint - The company reported a significant decline in revenue and net profit for the fiscal year 2025, primarily due to industry challenges and increased costs [1] Financial Performance - The total operating revenue for 2025 was 422.03 million yuan, representing a year-on-year decrease of 32.08% [1] - The net profit attributable to the parent company was 146.04 million yuan, down 40.84% compared to the previous year [1] Industry Challenges - The decline in performance is attributed to the impact of policies on the in vitro diagnostic industry, intensified competition in specific testing areas, and a less favorable pathogen prevalence compared to 2024 [1] Cost Factors - Increased human resources costs, research and development expenditures, and marketing investments contributed to the larger decline in profit metrics [1] Future Outlook - Despite the current challenges, the company has made progress in research and marketing, laying a foundation for development in 2026 [1]